Jurnal
Tanpa peringkat SINTA
Genetic Variants Influencing Spironolactone Effectiveness: A Pharmacogenomic Perspective
Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan · Vol. 14 No. 1 (2026) · hlm. 10–20
ISSN 2580-6874, 2339-269X
Terbit 2026-05-05
Penerbit FAKULTAS KEDOKTERAN DAN ILMU KESEHATAN UNIVERSITAS JAMBI
Bahasa en
Abstrak
Background: Spironolactone, a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, heart failure, and primary aldosteronism. However, significant interindividual variability in therapeutic response suggests a genetic contribution to its effectiveness. Method: This study employed a bioinformatics approach using secondary data from PharmGKB, GTEx Portal, and HaploReg v4.2 to identify genetic variants and gene expression profiles potentially influencing spironolactone response. Result: Seven variants were identified as associated with spironolactone effectiveness: rs1799752 (ACE), rs3890011 and rs1126742 (CYP4A11), rs1801253 (ADRB1), rs1799983 (NOS3), rs4961 (ADD1), and rs1042713 (ADRB2). Tissue-specific expression analysis showed ACE highly expressed in testis, CYP4A11 in liver, ADRB1 in lung, NOS3 in spleen, ADD1 in tibial artery, and ADRB2 in skin. Functional predictions indicated that missense variants (rs1126742, rs1799983, rs4961) may affect protein structure, while intronic variants (rs1799752, rs3890011) may influence gene regulation. Conclusion: These findings suggest that pharmacogenomic profiling may help predict spironolactone response and support the development of personalized treatment strategies. Further clinical validation is required to establish the therapeutic relevance of these variants
Jaringan kolaborasi para penulis
10 penulis ·
31 tautan kepenulisan bersama
· 13 lintas organisasi
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
Universitas Ahmad Dahlan Universitas Alma Ata Sekolah Tinggi Ilmu Kesehatan Samarinda Afiliasi tidak diketahui
Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.
Sumber metadata: OAI-PMH (metadata jurnal) https://online-journal.unja.ac.id/index.php/kedokteran/oai, pertama di-harvest 6 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title xml:lang="en">Genetic Variants Influencing Spironolactone Effectiveness: A Pharmacogenomic Perspective</dc:title>
<dc:creator xml:lang="en">Amukti, Danang Prasetyaning</dc:creator>
<dc:creator xml:lang="en">Pratami, Ria Indah</dc:creator>
<dc:creator xml:lang="en">Ananda, RA Dewinta Sukma</dc:creator>
<dc:subject xml:lang="en">Spironolactone</dc:subject>
<dc:subject xml:lang="en">Pharmacogenomics</dc:subject>
<dc:subject xml:lang="en">Genetic Variants</dc:subject>
<dc:subject xml:lang="en">Gene Expression</dc:subject>
<dc:subject xml:lang="en">Bioinformatics</dc:subject>
<dc:description xml:lang="en">Background: Spironolactone, a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, heart failure, and primary aldosteronism. However, significant interindividual variability in therapeutic response suggests a genetic contribution to its effectiveness.
Method: This study employed a bioinformatics approach using secondary data from PharmGKB, GTEx Portal, and HaploReg v4.2 to identify genetic variants and gene expression profiles potentially influencing spironolactone response.
Result: Seven variants were identified as associated with spironolactone effectiveness: rs1799752 (ACE), rs3890011 and rs1126742 (CYP4A11), rs1801253 (ADRB1), rs1799983 (NOS3), rs4961 (ADD1), and rs1042713 (ADRB2). Tissue-specific expression analysis showed ACE highly expressed in testis, CYP4A11 in liver, ADRB1 in lung, NOS3 in spleen, ADD1 in tibial artery, and ADRB2 in skin. Functional predictions indicated that missense variants (rs1126742, rs1799983, rs4961) may affect protein structure, while intronic variants (rs1799752, rs3890011) may influence gene regulation.
Conclusion: These findings suggest that pharmacogenomic profiling may help predict spironolactone response and support the development of personalized treatment strategies. Further clinical validation is required to establish the therapeutic relevance of these variants</dc:description>
<dc:publisher xml:lang="en">FAKULTAS KEDOKTERAN DAN ILMU KESEHATAN UNIVERSITAS JAMBI</dc:publisher>
<dc:date>2026-05-05</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://online-journal.unja.ac.id/kedokteran/article/view/43475</dc:identifier>
<dc:identifier>10.22437/jmj.v14i1.43475</dc:identifier>
<dc:source xml:lang="en">Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan; Vol. 14 No. 1 (2026): JAMBI MEDICAL JOURNAL: Jurnal Kedokteran dan Kesehatan; 10-20</dc:source>
<dc:source>2580-6874</dc:source>
<dc:source>2339-269X</dc:source>
<dc:language>en</dc:language>
<dc:relation>https://online-journal.unja.ac.id/kedokteran/article/view/43475/24309</dc:relation>
<dc:rights xml:lang="en">Copyright (c) 2026 Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan</dc:rights>
</oai_dc:dc>
Sitasi dan pengindeksan
OpenAlex
Terindeks
lewat DOI
0 sitasi
Crossref
Tidak ditemukan
Jumlah menurut tiap indeks pada 13 Nov 2026; setiap indeks menghitung sitasi dengan cara berbeda.
Sitasi artikel ini
APA 7
Amukti, D. P., Pratami, R. I., & Ananda, R. D. S. (2026). Genetic Variants Influencing Spironolactone Effectiveness: A Pharmacogenomic Perspective. Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan, 14(1), 10–20. https://doi.org/10.22437/jmj.v14i1.43475
Salin
IEEE
D. P. Amukti, R. I. Pratami, and R. D. S. Ananda, “Genetic Variants Influencing Spironolactone Effectiveness: A Pharmacogenomic Perspective,” Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan, vol. 14, no. 1, pp. 10–20, 2026, doi: 10.22437/jmj.v14i1.43475.
Salin
Dibuat dari metadata jurnal; periksa nama penulis sebelum dipakai.